186 related articles for article (PubMed ID: 29608578)
21. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial.
Huang PY; Wang CT; Cao KJ; Guo X; Guo L; Mo HY; Wen BX; Wu YS; Mai HQ; Hong MH
Eur J Cancer; 2013 May; 49(8):1923-31. PubMed ID: 23434149
[TBL] [Abstract][Full Text] [Related]
24. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
25. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.
Li H; Zhao T; Ji X; Liang S; Wang Z; Yang Y; Yin J; Wang R
Tumour Biol; 2016 Mar; 37(3):3535-42. PubMed ID: 26453118
[TBL] [Abstract][Full Text] [Related]
26. The impact of body mass index dynamics on survival of patients with advanced pancreatic cancer receiving chemotherapy.
Choi Y; Kim TY; Lee KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
J Pain Symptom Manage; 2014 Jul; 48(1):13-25. PubMed ID: 24321510
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
28. The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study.
Alarfi H; Salamoon M; Kadri M; Alammar M; Haykal MA; Alseoudi A; Youssef LA
BMC Res Notes; 2017 Nov; 10(1):550. PubMed ID: 29096707
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer.
Skírnisdóttir I; Sorbe B
Int J Gynecol Cancer; 2008; 18(2):345-51. PubMed ID: 17587318
[TBL] [Abstract][Full Text] [Related]
30. Regional chemotherapy in biliary tract cancers--a single institution experience.
Melichar B; Cerman J; Dvorák J; Jandík P; Mergancová J; Melicharová K; Tousková M; Krajina A; Voboril Z
Hepatogastroenterology; 2002; 49(46):900-6. PubMed ID: 12143237
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
[TBL] [Abstract][Full Text] [Related]
32. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
[TBL] [Abstract][Full Text] [Related]
33. Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer.
Jo J; Kwon HW; Park S; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Aug; 58(8):1255-1261. PubMed ID: 28254865
[TBL] [Abstract][Full Text] [Related]
34. Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Gennari A; Amadori D; Scarpi E; Farolfi A; Paradiso A; Mangia A; Biglia N; Gianni L; Tienghi A; Rocca A; Maltoni R; Antonucci G; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2016 Aug; 159(1):79-86. PubMed ID: 27460638
[TBL] [Abstract][Full Text] [Related]
35. Initial body mass indexes have contrary effects on change in body weight and mortality of patients on maintenance hemodialysis treatment.
Wiesholzer M; Harm F; Schuster K; Putz D; Neuhauser C; Fiedler F; Balcke P
J Ren Nutr; 2003 Jul; 13(3):174-85. PubMed ID: 12874741
[TBL] [Abstract][Full Text] [Related]
36. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
37. Body mass index does not affect the survival of pancreatic cancer patients.
Jiang QL; Wang CF; Tian YT; Huang H; Zhang SS; Zhao DB; Ma J; Yuan W; Sun YM; Che X; Zhang JW; Chu YM; Zhang YW; Chen YT
World J Gastroenterol; 2017 Sep; 23(34):6287-6293. PubMed ID: 28974895
[TBL] [Abstract][Full Text] [Related]
38. Complex relationship of body mass index with mortality in patients with critical limb ischemia undergoing endovascular treatment.
Murata N; Soga Y; Iida O; Yamauchi Y; Hirano K; Kawasaki D; Fujihara M; Tomoi Y
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):297-305. PubMed ID: 25524520
[TBL] [Abstract][Full Text] [Related]
39. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
[TBL] [Abstract][Full Text] [Related]
40. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
